16 completed, 3 unknown, 2 recruiting, 2 terminated. 26 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 26 | Completed 16, Unknown 3, Recruiting 2, Terminated 2, Active not recruiting 1, Enrolling by invitation 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow Neoplasms, Basal Cell: new trials by email Literature Review of Neoplasms, Basal Cell trials Research Report on Neoplasms, Basal Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Basal Cell Carcinoma Chemoprevention Trial 5% Imiquimod cream, Placebo Vehicle Control Cream - Basal Cell Carcinoma | Phase 3 | Recruiting | VA Office of Research and Development | 1630 | 2026-10-06 | 2026-11-02 |
| Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue Formulated Topical Methylene Blue (0.5 mg/mL), Wound Healing Gel - Advanced Basal Cell Carcinoma (BCC), Inoperable Disease | Phase 3 | Enrolling by invitation | Daryoush Hamidi Alamdari, PhD | 20 | 2025-10-21 | 2026-01-06 |
| Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib - Gorlin Syndrome | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 113 | 2024-03-17 | 2026-09-18 |
| Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial Nicotinamide, Placebo - Non-melanoma Skin Cancer, Carcinoma, Squamous Cell | Phase 3 | Recruiting | Women's College Hospital | 396 | 2023-08-28 | 2026-10-13 |
| The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma 5-Fluorouracil, SURGERY - Basal Cell Carcinoma, BCC | Phase 3 | Unknown | University of Aleppo | 40 | 2023-05-25 | 2024-01-02 |
| Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO Reduced dose intensity of IO - Lung Cancer Metastatic, Renal Cell Carcinoma | Phase 3 | Active not recruiting | UNICANCER | 646 | 2022-03-08 | 2026-07-17 |
| Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) Patidegib Topical Gel, 2% - Basal Cell Nevus Syndrome | Phase 3 | Terminated | Sol-Gel Technologies, Ltd. | 108 | 2020-06-03 | 2024-09-24 |
| Calcium Electroporation for Basal Cell Carcinomas - Proof of Concept Study Calcium chloride - Basal Cell Carcinoma | Phase 3 | Unknown | Bispebjerg Hospital | 25 | 2020-01-08 | 2021-09-16 |
| Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle - Basal Cell Nevus Syndrome | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 174 | 2019-02-19 | 2024-07-03 |
| Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Sinecatechins 10%, Placebo - Carcinoma, Basal Cell | Phase 2 / Phase 3 | Completed | Maastricht University Medical Center | 42 | 2014-11-01 | 2016-05-18 |
| Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy BF-200 ALA, methyl-aminolevulinate - Basal Cell Carcinoma (BCC) | Phase 3 | Completed | Biofrontera Bioscience GmbH | 281 | 2014-01-28 | 2022-11-03 |
| Fractional CO2 Laser Assisted Photodynamic Therapy Conventional photodynamic therapy, Fractional CO2 laser assisted PDT - Actinic Keratosis, Basal Cell Carcinoma | Phase 2 / Phase 3 | Completed | Bispebjerg Hospital | 47 | 2010-10-01 | 2015-07-30 |
| Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma Immunocryosurgery, Cryoimmunotherapy - Basal Cell Carcinoma | Phase 3 | Completed | University of Ioannina | 14 | 2009-02-01 | 2011-09-02 |
| Periocular Basal Cell Carcinoma (BCC): Permanent vs. Frozen Section Pathological Control Permanent Section Control, Frozen Section Control - Basal Cell Carcinoma | Phase 3 | Unknown | Queen's University | 290 | 2008-08-01 | 2011-07-12 |
| A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence Imiquimod 5% cream - Basal Cell Carcinoma | Phase 3 | Completed | Graceway Pharmaceuticals, LLC | 63 | 2004-01-01 | 2010-07-16 |
| Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer Photodynamic therapy with Metvix 160 mg/g cream - Actinic Keratosis, Warts | Phase 3 | Completed | Galderma R&D | 82 | 2003-07-25 | 2025-04-18 |
| Aldara for the Treatment of Large and/or Multiple sBCC Imiquimod - Carcinoma, Basal Cell | Phase 3 | Completed | MEDA Pharma GmbH & Co. KG | 111 | 2003-05-01 | 2022-02-22 |
| Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer imiquimod, conventional surgery - Non-melanomatous Skin Cancer | Phase 3 | Completed | Queen's Medical Center | 500 | 2002-10-01 | 2013-09-17 |
| A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma imiquimod - Basal Cell Carcinoma | Phase 3 | Completed | MEDA Pharma GmbH & Co. KG | 160 | 2001-02-01 | 2022-02-07 |
| Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma Photodynamic Therapy (PDT), Metvix cream, Placebo Cream - Basal Cell Carcinoma | Phase 3 | Completed | Galderma R&D | 65 | 2000-12-01 | 2024-08-05 |
Showing 20 of 26. Sign in to see all of them.
Carcinoma, Basal Cell (25) · Basal Cell Nevus Syndrome (5) · Carcinoma, Squamous Cell (4) · Keratosis, Actinic (3) · Basal cell carcinoma, multiple (1) · Bowen's Disease (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Melanoma (1) · Patient Compliance (1)
Carcinoma (26) · Neoplasms (26) · Neoplasms by Histologic Type (26) · Neoplasms, Glandular and Epithelial (26) · Abnormalities, Multiple (5) · Bone Cysts (5) · Bone Diseases (5) · Bone Diseases, Developmental (5) · Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Cysts (5) · Genetic Diseases, Inborn (5) · Jaw Cysts (5) · Jaw Diseases (5)
Imiquimod (4) · methyl 5-aminolevulinate (3) · Photochemotherapy (2) · 1-phenyl-3,3-dimethyltriazene (1) · Aminolevulinic Acid (1) · BF-200 ALA (1) · Calcium Chloride (1) · Eflornithine (1) · Electroporation (1) · Fluorouracil (1) · IPI-926 (1) · Niacinamide (1) · Surgical Procedures, Operative (1) · Tretinoin (1) · green tea extract polyphenone E (1)
Galderma R&D (4) · Sol-Gel Technologies, Ltd. (3) · Bispebjerg Hospital (2) · MEDA Pharma GmbH & Co. KG (2) · Biofrontera Bioscience GmbH (1) · Daryoush Hamidi Alamdari, PhD (1) · Graceway Pharmaceuticals, LLC (1) · Maastricht University Medical Center (1) · Novartis Pharmaceuticals (1) · QLT Inc. (1) · Queen's Medical Center (1) · Queen's University (1) · UNICANCER (1) · US Department of Veterans Affairs (1) · University of Aleppo (1)
Germany (7) · United States (7) · United Kingdom (6) · Denmark (5) · France (5) · Canada (4) · Italy (4) · Netherlands (4) · Spain (4) · Belgium (3) · Australia (2) · Greece (2) · Czechia (1) · Finland (1) · Iran (1)
Martin A. Weinstock, MD (2) · Ahmad Yamen Arnaout, M.D. (1) · An-Wen Chan (1) · Ann-Marie Wennberg, MD, PhD (1) · Carl Vinciullo, MD (1) · Colin Morton, Dr. (1) · Herma Neyndorff (1) · Ioannis D Bassukas, Professor (1) · Mara Ozolins, MS (1) · Nicole WJ Kelleners-Smeets, MD, PhD (1) · Noura Abdulrahman, M.D. (1) · Paul P. Carbone, MD (1)
PMID 19124815, PMID 19153339, PMID 20409337, PMID 24332516, PMID 27932240, PMID 29432644, PMID 37131154
2023 (1), U01CA077158 (1)